Cagrilintide
NN9838
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk, designed to mimic the satiety-inducing effects of the naturally occurring hormone amylin. It is administered as a once-weekly subcutaneous injection and is currently in Phase 3 clinical trials. Cagrilintide is a key component of the combination therapy CagriSema, paired with semaglutide for enhanced weight loss.
作用机制
Long-acting amylin analog that slows gastric emptying, promotes satiety, and reduces postprandial glucagon secretion. Works synergistically with GLP-1 agonists.
研究协议
仅供研究使用,非医疗建议。
Research protocols use 1.2mg to 4.5mg weekly. Dose escalation over 16 weeks. Often studied in combination with semaglutide.
研究笔记
Clinical Research Status
Cagrilintide is in Phase 3 development as both a standalone agent and as part of the CagriSema combination with semaglutide. The REDEFINE Phase 2 trial demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks as monotherapy. Novo Nordisk is positioning it primarily as a combination component rather than pursuing standalone approval initially.
Key Published Findings
Phase 2 data showed cagrilintide 4.5mg weekly produced significantly greater weight loss than placebo, with a distinct mechanism from GLP-1 agonists acting through amylin pathways. Amylin analogs slow gastric emptying, reduce glucagon secretion, and promote satiety through area postrema signaling. The combination with semaglutide showed additive effects beyond either agent alone in early trials.
Safety Profile
The most common adverse effects are gastrointestinal, including nausea and decreased appetite, consistent with amylin receptor activation. Injection site reactions have been reported but are generally mild and transient. Long-term safety data is still accumulating as Phase 3 trials continue, with particular attention to pancreatic safety signals.
Comparison to Related Compounds
Unlike pramlintide (Symlin), which requires three-times-daily dosing, cagrilintide's acylation technology enables once-weekly administration. It works through a complementary mechanism to GLP-1 agonists, targeting amylin rather than incretin pathways. The combination approach with semaglutide represents a multi-receptor strategy similar in concept to tirzepatide's dual GIP/GLP-1 action but using a physically separate co-formulation.
Community Observations
Research interest in cagrilintide centers primarily on its role within CagriSema rather than as a standalone compound. The amylin mechanism is understood to primarily enhance early meal satiety, complementing GLP-1's effects on sustained fullness. Clinical trial participants have reported that the combination produces qualitatively different appetite suppression compared to GLP-1 monotherapy.
半衰期
~7-10 days
复溶
Bacteriostatic water (BAC)
存储
冻干
Refrigerate 2-8C. Protect from light.
复溶后
Refrigerate 2-8C. Use within 28 days.
美国法律状态
又称作
常见问题
什么是 Cagrilintide?
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk, designed to mimic the satiety-inducing effects of the naturally occurring hormone amylin. It is administered as a once-weekly subcutaneous injection and is currently in Phase 3 clinical trials. Cagrilintide is a key component of the combination therapy CagriSema, paired with semaglutide for enhanced weight loss.
Cagrilintide 如何起作用?
Long-acting amylin analog that slows gastric emptying, promotes satiety, and reduces postprandial glucagon secretion. Works synergistically with GLP-1 agonists.
Cagrilintide 在美国的监管状态是什么?
Research chemical (not FDA-approved)
Cagrilintide 的半衰期是多少?
~7-10 days
Cagrilintide 还有哪些名称?
NN9838
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明